Logo Image
News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement

Brand Insights - Thought Leadership | Paid Program | Parexel

Effective governance models in CRO-sponsor partnerships: Lessons from the Bayer-Parexel collaboration

ByMelissa Bencivengo,Holger Liebig
August 1st 2025

Brand Insights - Thought Leadership | Paid Program

Uncovering Long-Term COVID in Drug Development

By
October 13th 2021

Brand Insights - Thought Leadership | Paid Program

How can clinical trials be designed to best study therapies for treating long COVID?

Can Synthetic Control Arms Address Regulatory and HTA Evidence Requirements?

June 1st 2021

Brand Insights - Thought Leadership | Paid Program

Advertisement
Advertisement

Trending on PharmExec

1

FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report

2

Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates

3

How Pharma is Adjusting Strategies for Changing Dynamics at FDA

4

FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry

5

FDA’s New Pilot Program and Real-Time Review of Clinical Data

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us